Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | P4HB | P07237 | 1/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7861615 | 1.00 | MAPT (0.50) | MAPTALDH1A1CYP3A4CYP2C9ALOX15 | |
| SCHEMBL7864584 | 1.00 | MAPT (0.50) | MAPTALDH1A1CYP3A4CYP2C9ALOX15 | |
| SCHEMBL7854681 | 0.92 | CYP3A4 (0.53) | MAPTALDH1A1CYP3A4CYP2C9ALOX15 | |
| Nyasol SCHEMBL8416158 | 0.87 | APP (0.43) | MAPTALDH1A1CYP3A4CYP2C9ALOX15 | |
| Nyasol SCHEMBL30712027 | 0.87 | APP (0.43) | MAPTALDH1A1CYP3A4CYP2C9ALOX15 | |
| Nyasol SCHEMBL776219 | 0.87 | APP (0.43) | MAPTALDH1A1CYP3A4CYP2C9ALOX15 | |
| Nyasol SCHEMBL799383 | 0.87 | APP (0.43) | MAPTALDH1A1CYP3A4CYP2C9ALOX15 | |
| Nyasol SCHEMBL776218 | 0.87 | APP (0.43) | MAPTALDH1A1CYP3A4CYP2C9ALOX15 | |
| SCHEMBL13558420 | 0.83 | CYP3A4 (0.46) | MAPTCYP3A4CYP2C9CYP2C19PTGS2 | |
| SCHEMBL7861271 | 0.83 | CYP3A4 (0.46) | MAPTCYP3A4CYP2C9CYP2C19PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | FABP4, ACACB, LIPC | MAPT 2597/4885ALDH1A1 475/4885CYP3A4 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.